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Abstract: Many patients with Alzheimer’s disease will develop agitation at later stages of 
the disease, which constitutes one of the most challenging and distressing aspects of dementia. 
Recently, nonpharmacological therapies have become increasingly popular and have been 
proven to be effective in managing the behavioral symptoms (including agitation) that are com-
mon in the middle or later stages of dementia. These therapies seem to be a good alternative 
to pharmacological treatment to avoid unpleasant side effects. We present a systematic review 
of randomized controlled trials (RCTs) focused on the nonpharmacological management of 
agitation in Alzheimer’s disease (AD) patients aged 65 years and above. Of the 754 studies 
found, eight met the inclusion criteria. This review suggests that music therapy is optimal for 
the management of agitation in institutionalized patients with moderately severe and severe 
AD, particularly when the intervention includes individualized and interactive music. Bright 
light therapy has little and possibly no clinically significant effects with respect to observational 
ratings of agitation but decreases caregiver ratings of physical and verbal agitation. Therapeutic 
touch is effective for reducing physical nonaggressive behaviors but is not superior to simulated 
therapeutic touch or usual care for reducing physically aggressive and verbally agitated behaviors. 
Melissa oil aromatherapy and behavioral management techniques are not superior to placebo 
or pharmacological therapies for managing agitation in AD. Further research in clinical trials 
is required to confirm the effectiveness and long-term effects of nonpharmacological interven-
tions for managing agitation in AD. These types of studies may lead to the development of 
future intervention protocols to improve the well-being and daily functioning of these patients, 
thereby avoiding residential care placement.
Keywords: dementia, nonpharmacological, behavioral and psychological symptoms
Introduction
Dementia is one of the most prevalent diseases in older people and constitutes the 
largest global public health care challenge. According to the 2015 World Alzheimer 
Report data,1 nearly 47 million people are living with dementia in 2015, a number 
that will nearly double every 20 years. Alzheimer’s disease (AD) is a specific form of 
dementia that causes as many as 50%–70% of all dementia cases.2 Although cognitive 
impairment is the central symptom of AD, behavioral and psychological symptoms, 
such as agitation, often coexist and are a common cause of patient and caregiver 
distress, institutionalization, and impairment in quality of life.3,4 Frequencies of agi-
tation between 13.0% and 50.4% have been reported across studies and settings,5–7 
and these increase as the severity of dementia progresses. Agitation has been defined 
as “inappropriate verbal, vocal, or motor activity that is not explained by needs or 
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confusion per se”.8 Although there is no consensus regarding 
specific behaviors that integrate the concept,4 clinicians have 
identified three subtypes of agitation as follows: physically 
nonaggressive behavior, aggressive behavior, and verbally 
agitated behavior.9 Interestingly, there appears to be a rela-
tionship between agitation and unmet needs originated by 
a decreased ability to cope with environmental stimulation 
and to communicate these needs.10
Pharmacological interventions have been traditionally 
used in the treatment of agitation, but many studies have 
documented adverse effects of sedative and antipsychotic 
drugs, such as worsening cognitive function, higher cerebro-
vascular side effects, longer hospitalizations, and increased 
mortality.11 Thus, the use of a nonpharmacological approach 
as a first-line treatment for agitation in dementia patients 
has been increasingly recommended.12,13 Overall, well-
conducted, evidence-based studies on nonpharmacological 
interventions are lacking. Nonpharmacological approaches 
address the contextual and/or psychosocial reasons for 
agitation and avoid the potentially negative side effects of 
pharmacological treatment. Interventions such as cognitive 
stimulation/training, behavioral interventions, physical exer-
cise, therapeutic touch, aromatherapy, bright light therapy, 
music therapy, and multisensory stimulation have shown 
promising results in decreasing agitation and cognitive 
impairment in older adults with dementia.14,15
We performed a systematic review of randomized con-
trolled trials (RCTs) focusing on the nonpharmacological 
management of agitation of AD patients, with the aim of 
making evidence-based recommendations about the use 
of specific intervention strategies. Previous systematic 
reviews on the topic have been published, including studies 
with dementia patients, but none of these studies analyzed 
their results according to dementia subtypes.12,14–17 Because 
patients with different subtypes of dementia or different 
levels of cognitive impairment may present with different 
levels of agitation and respond differently to interventions, 
we specifically focused this review on AD patients aged 
65 years and above.
This paper had three specific aims as follows: 1) to 
review the literature on nonpharmacological therapies 
used to manage agitation in older AD patients over the 
past 20 years, 2) to assess the specific effectiveness of each 
nonpharmacological therapy, and 3) to provide evidence-
based recommendations about the use of specific therapies 
and future research on this topic. Exploring these aspects is 
clinically relevant and has important implications for health 
service planning.
Methods
Data sources and search strategy
A systematic review of the literature published during the 
past 20 years (January 1996 to June 2015) was performed. 
Four computerized electronic databases were searched, 
including PubMed, Web of Science, PsycINFO, and Sco-
pus, using the following keywords for AD, agitation, and 
non-pharmacological therapy: randomized controlled trial, 
Alzheimer*, agitat*, agress*, non-pharmacological, non-drug 
therap*, acupuncture, aromatherapy, light therap*, mas-
sage, touch, music*, group exercise*, activities, snoezelen, 
multisensory stimulation, social contact*, environmental 
modification*, caregiver training, behavioral or behavioral 
management, psychosocial, reminiscence therap*, valida-
tion therap*, reality orientation, space retrieval, alternative 
therap*, intervention*, and staff training.
Two independent reviewers evaluated appropriateness 
of inclusion, and conflicts were discussed until a consensus 
was reached. In cases in which a consensus was not reached, 
a third reviewer was involved.
Inclusion and exclusion criteria
We included original scientific articles in English that met 
the following criteria: 1) Population: AD patients (65 years 
of age or older, or a mean age of at least 75 if no age ranges 
were provided). Studies were selected if they reported a vali-
dated or medical diagnosis of AD, and they were excluded 
if they included patients with other subtypes of dementia; 
2) Intervention: nonpharmacological interventions aimed at 
managing agitated behaviors were included; 3) Type of experi-
mental design: RCTs comparing agitation before and after 
interventions were included. In terms of the level of evidence, 
all studies were considered to be level 2 based on the Oxford 
Centre for Evidence-Based Medicine (CEBM) criteria;18 
4) Outcome: Only studies exploring nonpharmacological 
interventions for agitation as a primary outcome (measured 
quantitatively and with a validated scale) or studies including 
sufficient information to determine the effect of nonpharma-
cological intervention on agitation were included; 5) Type of 
study: Only original articles were included. Abstracts, reviews, 
descriptive studies, and studies based on the description of a 
protocol, as well as studies based on the perspective of the 
authors, books, short surveys, observational studies, comments 
on an article, and conference abstracts, were excluded.
Data extraction
Studies were synthesized according to the following char-
acteristics: author and year, country, sample characteristics 
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(age and sex), study design, level of cognitive impairment, 
type of intervention, agitation scale, and main findings. 
A narrative synthesis approach was performed to examine 
the results. Next, we made recommendations about the clini-
cal use for each nonpharmacological intervention based on 
the main findings.
Results
The review procedure is described in Figure 1. As shown 
in the figure, a total of 754 studies were identified; after 
the removal of duplicates, 476 were considered potentially 
relevant and were screened for relevant content. From these 
studies, 402 were excluded on the basis of the title and 
abstract, and 74 were retrieved for full-text assessment. 
In the next phase, 66 were excluded based on the inclusion 
criteria. Finally, eight studies met the inclusion criteria for 
the review (Figure 1).
Data synthesis
Studies’ characteristics
The characteristics of the studies are listed in Table 1. The 
eight studies that were included provided data on the effec-
tiveness of music therapy (n=3),19–21 bright light therapy 
(n=2),22,23 aromatherapy (n=1),24 therapeutic touch (n=1),25 
and psychological interventions with caregivers using behav-
ioral management techniques (BMT) (n=1).26
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Figure 1 Flowchart of systematic literature search.
Abbreviation: AD, Alzheimer’s disease. 
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The sample size of the included studies ranged from 3719 to 
14826 AD participants. Three studies were from Europe,19,21,24 
whereas three studies were from the United States,22,23,26 one 
study was from Asia,20 and one study was from Canada.25 All 
studies except one26 included institutionalized AD patients 
in care homes. Two were multicenter studies.24,26
Of the eight included studies, four studies22–24,26 used the 
National Institute of Neurological and Communication Disor-
ders and Stroke/Alzheimer’s Disease and Related Disorders 
Association (NINCDS/ADRDA) clinical criteria for AD,27 
whereas two studies19,20 used the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) criteria for AD,28 one 
study21 diagnosed AD according to International Classifica-
tion of Diseases, Tenth Edition (ICD-10), and one study25 
did not report to specific criteria, but the AD diagnosis was 
confirmed from the medical records of each patient.
Regarding the scales used to assess agitation, two 
studies19,25 used the Cohen-Mansfield Agitation Inventory 
(CMAI),9 which assesses the frequency of agitated behavior 
in a 7-point rating scale, with a higher score indicating more 
agitation. Two studies20,21 used the Behavioral Pathology in 
Alzheimer’s Disease rating scale (BEHAVE-AD),29 which 
covers behavioral symptoms in seven categories: paranoid 
and delusional ideations, hallucinations, activity distur-
bances, aggressiveness, diurnal rhythm disturbances, affec-
tive disturbances, and anxieties and phobias, with a higher 
score indicating more severity. One study23 used the Neu-
ropsychiatric Inventory-Nursing Home (NPI-NH),30 which 
assesses either ten or 12 behavioral disturbances common 
in dementia as follows: delusions, hallucinations, dysphoria, 
anxiety, agitation or aggression, euphoria, disinhibition, 
irritability or lability, apathy, aberrant motor activity, sleep 
and nighttime behavior disturbances, and appetite and eat-
ing changes, with a higher score indicating greater severity. 
In the study by Ancoli-Israel et al,22 agitation was assessed 
both with the CMAI9 and the Agitated Behavior Rating Scale 
(ABRS).31 The ABRS is a behavioral observation rating scale 
of the following five major behaviors: manual manipula-
tion, restraint escape, searching or wandering, tapping or 
banging, and vocalization, with a higher score indicating 
more severity. In the study by Burns et al,24 agitation was 
assessed using both the Pittsburg Agitation Scale (PAS)32 
and the NPI.30 The PAS is a 16-item observational scale that 
rates the severity of agitation from 0 to 4 using the following 
four general behavior groups: aberrant vocalization, motor 
agitation, aggressiveness, and resisting, with a higher score 
indicating more agitation. In the study by Teri et al,26 agita-
tion was assessed with the CMAI9 and Agitated Behavior 
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Inventory for Dementia (ABID).33 The ABID consists of 
16 items designed specifically to evaluate the frequency 
of common agitated behaviors and caregiver reactions in 
community-residing dementia patients. Most studies19,22,23,25,26 
evaluated cognitive status by administering the Mini–Mental 
State Examination (MMSE).34
Description of the studies
Studies were organized according to the types of nonpharma-
cological therapy, which are briefly described using Medical 
Subject Headings (MeSH) definitions.
Music therapy
Music therapy is the use of music as an adjunctive therapy in 
the treatment of neurological, mental, or behavioral disorders. 
Three studies19–21 provided evidence of the effectiveness of 
music therapy for reducing agitation in institutionalized 
patients with moderately severe and severe AD. This result 
was particularly strong when the intervention included 
individualized (related to special positive memories of the 
participants) and interactive (including clapping, singing, 
and dancing) music.20
One RCT19 compared the short- and long-term effects 
of participative music and cooking interventions lasting 
4 weeks and reported that both types of pleasant intervention 
decreased the severity of agitation measured using the CMAI9 
and NPI.30 The intervention group (n=18) received two 1-hour 
sessions a week of participatory music therapy (listening to 
music, singing, and playing percussion instruments), and 
the control group (n=19) received a cooking intervention 
(preparing a recipe). Importantly, in the music therapy group, 
the decrease in agitated behaviors was significant during the 
intervention (after the fourth session) but not at the end or 
at the follow-up evaluations (2 and 4 weeks after the inter-
vention). Moreover, this study did not include a no-contact 
group to ensure that behavioral improvement did not result 
from increasing familiarity with the supervisor, who had no 
previous education in music therapy. Because the authors did 
not take into account individual music preferences, and the 
supervisor (psychologist) was not a qualified music therapist 
(and he/she was more comfortable in cooking), the benefit of 
music therapy observed in this study may have been reduced. 
Importantly, the improvement in agitation was stronger in the 
cooking intervention, suggesting that the observed benefits 
were not specific to musical interventions.
The other RCT20 explored the long-term effects of passive 
(listening to music via a CD player) or interactive (includ-
ing clapping, singing, and dancing) music therapy lasting 
10 weeks using the BEHAVE-AD29 and reported a higher, 
long-term reduction in behavioral symptoms in the interactive 
music group (n=13) compared with the passive music group 
(n=13) and no-music control group (n=13). Particularly, the 
scores of five items of the BEHAVE-AD were significantly 
reduced in the interactive group: paranoid and delusional 
ideations, activity disturbances, aggressiveness, affective 
disturbances, and anxieties and phobias; however, this effect 
disappeared 3 weeks after the music intervention, indicat-
ing the need for regularly conducted music interventions to 
maintain the beneficial effects. The music facilitators included 
two music therapists, four occupational therapists, and 
six nurses. Each intervention was performed once a week and 
lasted 30 minutes, and individualized music related to specific 
positive memories for each participant was selected.
In a case-control study,21 a significant reduction was 
observed in activity disturbances, aggressiveness, and anxiety 
measured using the unpublished Icelandic version of the 
BEHAVE-AD29 in a music therapy group during a 6-week 
period, although this effect had mostly disappeared 1 month 
later. In this study, the music intervention (n=20) was 
30 minutes of music therapy delivered three times a week, 
whereas the control (n=18) was usual care. A qualified music 
therapist performed the intervention after the selection of a 
collection of songs familiar to the elderly. Each song was 
sung twice during the sessions, and every patient participated 
actively (singing, playing instruments, or dancing) or pas-
sively (holding the songbook and listening).
Bright light therapy
Light therapy is the exposure to light, particularly by vari-
ously concentrated light rays or specific wavelengths. Two 
studies22,23 examined the efficacy of bright light therapy in 
decreasing agitated behaviors in AD patients, and these results 
showed that this therapy had little and possibly no clinically 
significant effects. One of the RCTs22 including AD patients 
with significant agitation at baseline examined both caregiver 
perceptions of the agitated behavior using the CMAI9 and the 
direct observation of agitated behaviors using the ABRS.31 The 
researchers found that increasing light exposure (2,500 lux) 
significantly decreased caregiver ratings of physical and verbal 
agitation after intervention, but caregiver ratings also decreased 
in the control group. They also reported that bright light had 
no significant effects on the observational ratings of agitation 
in any of the light-treatment groups, although morning bright 
light treatment delayed the timing (but not the strength) of 
agitation.22 Importantly, they also observed a worsening of 
verbal agitation in the evening bright light group.
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The other RCT23 explored the effect of timed morning 
(n=29) or afternoon bright light (n=24) exposure at 2,500 
lux for 1 hour daily compared with usual indoor light levels 
(n=17; 150–200 lux) in AD patients who experienced 
rest–activity disruption at baseline. They found a significant 
but clinically small worsening in agitation/aggression as 
measured with the NPI-NH30 after 10 weeks of treatment, 
particularly in the morning-light group. Importantly, the nurs-
ing staff was not unaware of the experimental condition of 
the participants, and the effect of interrater variability on the 
observed results was impossible to determine in this study.
Aromatherapy
Aromatherapy is the use of fragrances and essences from 
plants to affect or alter a person’s mood or behavior and 
facilitate physical, mental, and emotional well-being. A mul-
ticenter, double-blind, placebo RCT24 explored the effects 
of aromatherapy with Melissa officinalis oil in the treatment 
of agitation in institutionalized AD patients with a previous 
history of significant agitation, and found that intervention 
with Melissa oil (n=32) was not superior to placebo (n=31) 
or pharmacological therapy with donepezil (5 mg/day, n=31) 
after 4 or 12 weeks of treatment. Agitation was assessed by 
the PAS32 and NPI.30 The application of Melissa oil occurred 
twice a day and involved massaging the oil into the hands 
and upper arms for 1–2 minutes. Given the substantial 
improvement in the placebo group, the authors emphasized 
the potential benefits of meeting regularly (touch and social 
interaction) with care staff in the management of agitation 
in AD patients.
Therapeutic touch
Therapeutic touch is an intentionally directed process dur-
ing which the practitioner places his or her hands upon the 
person to be cured with the intent of spiritual energetic heal-
ing. One RCT25 compared the effectiveness of therapeutic 
touch intervention (n=17), which was administered daily 
for 30–40 minutes for 5 consecutive days, with a simulated 
therapeutic touch intervention (n=16) and with usual care 
(n=18) in institutionalized AD patients with a previous his-
tory of agitated behaviors. The therapeutic touch intervention 
was conducted by nurses who had completed the advanced 
level of a therapeutic touch and healing program, and the 
simulated therapeutic touch intervention was conducted 
by nursing and health-related volunteer students. Agitation 
levels were measured at various times after treatment and 
then compared. Therapeutic touch was effective in reducing 
the frequency of physical nonaggressive behaviors (pacing, 
repetitious movements, and general restlessness) but was 
not superior to simulated therapeutic touch or usual care 
in reducing physically aggressive and verbally agitated 
behaviors. It is important to note, however, that a significant 
decrease in the number of all analyzed agitated behaviors 
was observed in the three groups from baseline to the end of 
intervention, although this reduction was significantly lower 
in the usual care group.
Psychological intervention with family caregivers
Psychological therapies imply the use of specific psychologi-
cal techniques or approaches for the reduction of behavioral 
symptoms in dementia. One multicenter, placebo RCT26 
reported that a psychological intervention with family care-
givers (spouses or adult relatives) by training in BMT (n=41) 
was not superior to pharmacological therapy with haloperi-
dol (mean dose, 1.8 mg/d; n=34), trazodone (mean dose, 
200 mg/d; n=37), or placebo (n=36) in reducing agitation in 
AD outpatients with a previous history of significant agita-
tion and moderate-to-severe cognitive impairment, although 
it slightly reduced the incidence of adverse events such as 
bradykinesia and parkinsonian gait after 16 weeks of treat-
ment. No long-term effects of the intervention were found at 
3-, 6-, and 12-month follow-ups. In this study, the intervention 
was performed by expert therapists with master’s degrees and 
consisted of eleven structured sessions that provided informa-
tion about AD strategies to decrease agitation, and structured 
in- and out-of-session assignments, including a videotaped 
training program. The treatment protocol was general due to 
the diversity of the participants, and the authors suggest that a 
more individualized BMT may have yielded better results.
Discussion
The purpose of this review was to identify and synthesize 
available research evidence on the efficacy of the nonphar-
macological management of agitation in older adults with 
AD and to make evidence-based recommendations about 
the clinical use of different interventions in this population. 
The focus on AD is relevant, because the treatment effects 
on agitation may be different depending on the subtype and 
the severity of dementia. There is also evidence of more 
agitation in patients with AD than in patients with vascular 
dementia or other types of dementia.35
effective nonpharmacological therapies to 
manage agitation in AD
On the basis of the methodological quality of the three 
included studies exploring the effectiveness of music therapy 
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in AD,19–21 we concluded that music therapy performed by 
qualified music therapists is an optimal intervention in insti-
tutionalized AD patients. The effectiveness of this type of 
therapy in reducing agitated behaviors has been reported in 
previous systematic reviews with dementia patients,14,15,17,36–38 
particularly when based on individual music choices and when 
complemented by group interventions. Thus, it appears that 
music therapy is effective for managing agitation in institu-
tionalized dementia patients, potentially because it can engage 
interest and provides an opportunity for social interaction.
It is important to note that in the three studies, agitated 
behaviors returned to baseline levels at follow-up, suggesting 
that music therapy interventions must be implemented on a 
long-term basis to maintain their beneficial effects. Moreover, 
the long-term benefits of music therapy remain unclear and 
require further investigation.
One of the three studies19 included participants with some 
previous agitation, whereas the other two studies20,21 did not 
clearly report the previous history of agitation. Thus, the 
effect of music therapy in AD patients with severe baseline 
agitation has not been specifically investigated.
Low number and variability among the included stud-
ies makes it difficult to identify the most effective duration 
and frequency of the music intervention. The researchers 
completed therapy over several weeks (4–10 weeks), with 
the sessions lasting 30–60 minutes and occurring 1, 2, or 
3 times a week; thus, a minimum of 30 minutes of interac-
tive and individualized music therapy twice a week appears 
reasonable in AD patients. The three trials were small; thus, 
to strengthen the above evidence, future studies should 
include larger samples. Finally, it is important to note that 
the sample was predominantly female, making it difficult 
to explore differences between the sexes with respect to the 
effectiveness of music therapy.
Nonpharmacological therapies requiring 
more research
The inconclusive results of the two studies exploring the 
effectiveness of bright light therapy22,23 and the fact that it 
may slightly worsen symptomatic agitation indicate that 
future research is necessary to examine the actual effect of 
bright light exposure on agitated behaviors in AD patients.
The study by Burns et al24 provided strong evidence 
indicating that there is no benefit for aromatherapy with 
Melissa oil in the management of agitation in AD, at least 
over a 12-week period of intervention. Consistent with this 
finding, a recent systematic review39 of RCTs including 
dementia patients of any type and severity reported equivocal 
benefits with aromatherapy.
Regarding the effectiveness of therapeutic touch, the 
results obtained by Hawranick et al25 provided evidence of the 
modest potential for this therapy in treating agitated but not 
physically aggressive behaviors in AD patients with severe 
cognitive impairment, but additional research is required to 
obtain evidence about its long-term effects because it con-
stitutes an inexpensive method that can be implemented by 
family caregivers or staff.
Regarding psychological interventions involving train-
ing of family caregivers to use BMT, the study by Teri 
et al26 provides strong evidence of modest and comparable 
reductions in agitation with placebo and active treatments 
(both pharmacological and nonpharmacological), suggesting 
that training family caregivers with this technique is not an 
optimal clinical alternative for the management of agitation 
in AD outpatients.
Consistent with these findings, a recent systematic review 
found inconclusive evidence regarding the efficacy of these 
therapies in improving agitation in dementia and recom-
mended further research on the topic.15
Challenges and solutions
Optimal management of agitation in AD constitutes a major 
clinical challenge to avoid or delay institutionalization and 
to improve quality of life for patients and caregivers. On the 
basis of the present literature review, there are some questions 
that merit further investigation. First, there is insufficient 
evidence in the literature about the effectiveness of nonphar-
macological therapies in noninstitutionalized AD patients and 
the long-term effects of these interventions. Future studies 
in home and community settings are particularly relevant 
to determine if nonpharmacological therapies can delay or 
avoid residential care placement. Second, all included studies 
implemented interventions in AD patients with significant 
cognitive impairment, but the benefits of nonpharmacological 
therapy on patients with milder forms of AD may be under-
estimated. Third, future studies should include a detailed 
description of the previous history of agitation to distinguish 
between spontaneous or reactive agitation. Indeed, in our 
opinion, the identification of the underlying causes (and 
biological mechanisms) and the severity of agitation in AD 
patients is crucial and may assist clinicians and researchers 
in designing effective nonpharmacological interventions. AD 
patients usually present multiple comorbidities that may act 
as behavioral risk factors, and these can have an important 
impact on the effectiveness of the nonpharmacological 
therapies. Evaluating for their presence and addressing them 
is equally important to implement personalized interventions 
for agitation management.
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Given the limited evidence currently available regarding 
the efficacy of nonpharmacological therapies to manage 
agitation in AD, there is a strong need for further and more 
rigorous research. In recent years, multisensory stimulation 
(MSS) has become a commonly used approach to manage 
behavioral disturbances and to promote positive mood in 
dementia patients. MSS actively stimulates the senses of 
hearing, touch, vision, and smell in an individual-oriented, 
nonthreatening environment. It is intended to provide 
individualized, sensory stimulation without the need for 
higher intellectual activity to achieve or maintain a state 
of well-being and may be useful in the management of 
agitation in AD. In previous studies and reviews, it has 
been demonstrated that MSS produces immediate or 
short-term positive effects on behavior and mood.38,40–46 
Future studies are required to assess its effectiveness in 
this dementia subtype.
Importantly, in the present study, we included only 
RCTs; it was recently suggested that this likely excludes 
potent interventions in dementia patients, which limits 
conclusions.36 Finally, we would like to highlight that 
although we have made some recommendations providing 
valuable practical information about the optimal manage-
ment of agitation in AD patients based on the level of 
evidence of the reviewed studies, these recommendations 
are not definitive because clinicians should take into 
consideration the specific characteristics of their patients 
or alternative/complementary treatments before using a 
specific intervention.47
Conclusion
This review found that music therapy is an effective 
nonpharmacological intervention for reducing agitation 
in institutionalized AD patients, particularly when the 
intervention implies individualized and interactive music. 
However, more evidence regarding the long-term effects 
of this therapy is needed. Bright light therapy has little and 
potentially no clinically significant effects on agitation 
levels. Therapeutic touch is effective for reducing physical 
nonaggressive behaviors but is not superior to simulated 
therapeutic touch or usual care in reducing physically 
aggressive and verbally agitated behaviors. Melissa aro-
matherapy and BMT do not appear to be superior to phar-
macological therapies or placebo in managing agitation in 
AD patients; more evidence about their effects on agitation 
is needed to make definitive clinical recommendations. In 
general, there is a severe paucity of research into the effects 
of nonpharmacological therapies in managing agitation in 
older AD patients.
Author contributions
JCM made the conception of the study and design. CD and 
BA developed the search strategies, independently screened 
the title and abstracts of the 754 articles extracted from the 
literature search, applied the inclusion/exclusion criteria, 
and retrieved the full electronic text of the eight selected 
articles. LL and BA extracted the relevant data from the 
selected articles (independently). LL, BA, and JCM drafted 
the manuscript. AM and IG provided feedback on the pro-
tocol during its development and edited the manuscript. All 
authors contributed toward data analysis, drafting and criti-
cally revising the paper and agree to be accountable for all 
aspects of the work. All authors read and approved the final 
version of the manuscript.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Alzheimer’s Disease International (AZ). World Alzheimer Report 2015. 
London, UK: Alzheimer’s Disease International; 2015. Available 
from: http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf. 
Accessed September 28, 2015.
 2. Quiu C, Kivipelto M, Strauss, E. Epidemiology of Alzheimer’s disease: 
occurrence, determinants, and strategies toward intervention. Dialogues 
Clin Neurosci. 2009;11:111–128.
 3. Hay DP, Klein TT, Hay LK, Grossberg GT, Kennedy JS. Agitation 
in Patients with Dementia: A Practical Guide to Diagnosis and Man-
agement. 1st ed. Washington, DC: American Psychiatric Publishing; 
2003.
 4. Kong E. Agitation in dementia: concept clarification. J Adv Nurs. 2005; 
52:526–536.
 5. Kverno KS, Rabins PV, Blass DM, Hicks K, Black BS. Prevalence 
and treatment of neuropsychiatric symptoms in hospice-eligible nurs-
ing home residents with advanced dementia. J Gerontol Nurs. 2008; 
34:8–17.
 6. Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, 
Langa KM. Prevalence of neuropsychiatric symptoms and their asso-
ciation with functional limitations in older adults in the United States: 
the aging, demographics, and memory study. J Am Geriatr Soc. 2010; 
58:330–337.
 7. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence 
of neuropsychiatric symptoms in dementia: the Cache County study. 
Int J Geriatr Psychiatry. 2008;23:170–177.
 8. Cohen-Mansfield J, Billing N. Agitated behaviors in the elderly. I. 
A conceptual review. J Am Geriatr Soc. 1986;34:711–721.
 9. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation 
in a nursing home. J Gerontol. 1989;44:M77–M84.
 10. Cohen-Mansfield J, Dakheel-Ali M, Marx MS, Thein K, Regier NG. 
Which unmet needs contribute to behavior problems in persons with 
advanced dementia? Psychiatry Res. 2015;228:59–64.
 11. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of 
atypical antipsychotics for dementia: meta-analysis of randomized, 
placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191–210.
 12. Olazarán J, Reisberg B, Clare L, et al. Nonpharmacological therapies in 
Alzheimer’s disease: a systematic review of efficacy. Dement Geriatr 
Cogn Disord. 2010;30:161–178.
 13. Panza F, Solfrizzi V, Seripa D, et al. Progresses in treating agitation: 
a major clinical challenge in Alzheimer’s disease. Expert Opin Phar-
macother. 2015;16:1–8.
Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treatments 
intended to prevent or delay the onset of maladaptive correlates of aging 
in human beings. This journal is indexed on PubMed Central, MedLine, 
CAS, Scopus and the Elsevier Bibliographic databases. The manuscript 
management system is completely online and includes a very quick and fair 
peer-review system, which is all easy to use. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Clinical Interventions in Aging 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
184
Millán-Calenti et al
 14. Livingston G, Kelly L, Lewis-Holmes E, et al. A systematic review of 
the clinical effectiveness and cost-effectiveness of sensory, psychologi-
cal and behavioural interventions for managing agitation in older adults 
with dementia. Health Technol Assess. 2014;18(39):1–226.
 15. Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological 
interventions for agitation in dementia: systematic review of randomised 
controlled trials. Br J Psychiatry. 2014;205:436–442.
 16. Kong E, Evans LK, Guevara JP. Nonpharmacological intervention for 
agitation in dementia: a systematic review and meta-analysis. Aging 
Ment Health. 2009;13:512–520.
 17. Staedtler AV, Nunez D. Nonpharmacological therapy for the manage-
ment of neuropsychiatric symptoms of Alzheimer’s disease: linking evi-
dence to practice. Worldviews Evid Based Nurs. 2015;12:108–115.
 18. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels 
of Evidence. Oxford Centre for Evidence-Based Medicine. Available 
from: http://www.cebm.net/index.aspx?o=5653. Accessed September 
28, 2015.
 19. Narme P, Clément S, Ehrlé N, et al. Efficacy of musical interventions 
in dementia: evidence from a randomized controlled trial. J Alzheimers 
Dis. 2014;38:359–369.
 20. Sakamoto M, Ando H, Tsutou A. Comparing the effects of different 
individualized music interventions for elderly individuals with severe 
dementia. Int Psychogeriatr. 2013;25:775–784.
 21. Svansdottir HB, Snaedal J. Music therapy in moderate and severe 
dementia of Alzheimer’s type: a case-control study. Int Psychogeriatr. 
2006;18:613–621.
 22. Ancoli-Israel S, Martin JL, Gehrman P, et al. Effect of light on agitation 
in institutionalized patients with severe Alzheimer disease. Am J Geriatr 
Psychiatry. 2003;11:194–203.
 23. Dowling GA, Graf CL, Hubbard EM, Luxenberg JS. Light treatment 
for neuropsychiatric behaviors in Alzheimer’s disease. West J Nurs Res. 
2007;29:961–975.
 24. Burns A, Perry E, Holmes C, et al. A double-blind placebo-controlled 
randomized trial of Melissa officinalis oil and donepezil for the treat-
ment of agitation in Alzheimer’s disease. Dement Geriatr Cogn Disord. 
2011;31:158–164.
 25. Hawranik P, Johnston P, Deatrich J. Therapeutic touch and agitation in indi-
viduals with Alzheimer’s disease. West J Nurs Res. 2008;30:417–434.
 26. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: 
a randomized, placebo-controlled clinical trial. Neurology. 2000;55: 
1271–1278.
 27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, 
Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the 
NINCDS-ADRDA Work Group under the auspices of Department 
of Health and Human Services Task Force on Alzheimer’s Disease. 
Neurology. 1984;34:939–944.
 28. American Psychiatric Association. Diagnostic and Statistical Manual 
of Mental Disorders, (DSM-IV). 4th ed. Washington, DC: American 
Psychiatric Association; 1994.
 29. Reisberg B, Borenstein B, Salob SP, Ferris SH, Franssen E, Georgotas A. 
Behavioral symptoms in Alzheimer’s disease: phenomenology and 
treatment. J Clin Psychiatry. 1987;48:9–15.
 30. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, 
Gombein J. The neuropsychiatric inventory: comprehensive assessment 
of psychopathology in dementia. Neurology. 1994;44:2308–2314.
 31. Bliwise DL, Lee KA. Development of an agitated behavior rating scale 
for discrete temporal observations. J Nurs Meas. 1993;1:115–124.
 32. Rosen J, Burgio L, Kollar M, et al. The Pittsburg Agitation Scale: 
a user friendly instrument for rating agitation in dementia patients. Am 
J Geriatr Psychiatry. 1994;2:52–59.
 33. Logsdon RG, Teri L, Weiner MF, et al. Assessment of agitation 
in Alzheimer’s disease: the agitated behavior in dementia scale. 
Alzheimer’s disease cooperative study. J Am Geriatr Soc. 1999;47: 
1354–1358.
 34. Folstein M, Folstein SE, McHugh PR. Mini-mental state: a practical 
method for grading the cognitive state of patients for the clinician. 
J Psychiatr Res. 1975;12:189–198.
 35. Zuidema S, Koopmans R, Verhey, F. Prevalence and predictors of 
neuropsychiatric symptoms in cognitively impaired nursing home 
patients. J Geriatr Psychiatry Neurol. 2007;20:41–49.
 36. Cohen-Mansfield J. Non-pharmacological interventions for agitation in 
dementia: various strategies demonstrate effectiveness for care home 
residents; further research in home settings is needed. Evid Based Nurs. 
2016;19(1):31.
 37. Forbes DA, Peacock S, Morgan D. Nonpharmacological management 
of agitated behaviours associated with Dementia. Geriatr Aging. 
2005;8(4):26–30.
 38. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG; Old Age 
Task Force of the World Federation of Biological Psychiatry. Systematic 
review of psychological approaches to the management of neuropsychi-
atric symptoms of dementia. Am J Psychiatry. 2005;162:1996–2021.
 39. Forrester LT, Maayan N, Orrell M, Spector AE, Buchan LD, Soares-
Weiser K. Aromatherapy for dementia. Cochrane Database Syst Rev. 
2014;2:CD003150.
 40. Baker R, Holloway J, Holtkamp CC, et al. Effects of multi-sensory 
stimulation for people with dementia. J Adv Nurs. 2003;43:465–477.
 41. Collier L, McPherson K, Ellis-Hill C, Staal J, Bucks R. Multisensory 
stimulation to improve functional performance in moderate to severe 
dementia-interim results. Am J Alzheimers Dis Other Demen. 2010; 
25:698–703.
 42. Maseda A, Sánchez A, Marante MP, González-Abraldes I, Buján A, 
Millán-Calenti JC. Effects of multisensory stimulation on a sample of 
institutionalized elderly people with dementia diagnosis: a controlled lon-
gitudinal trial. Am J Alzheimers Dis Other Demen. 2014;29:463–473.
 43. Maseda A, Sánchez A, Marante MP, González-Abraldes I, de Labra C, 
Millán-Calenti JC. Multisensory stimulation on mood, behavior, and 
biomedical parameters in people with dementia: is it more effective 
than conventional one-to-one stimulation? Am J Alzheimers Dis Other 
Demen. 2014;29:637–647.
 44. Sánchez A, Millán-Calenti JC, Lorenzo-López L, Maseda A. 
Multisensory stimulation for people with dementia: a review of the 
literature. Am J Alzheimers Dis Other Demen. 2012;28:7–14.
 45. Sánchez A, Marante-Moar MP, Sarabia C, et al. Multisensory stimula-
tion as an intervention strategy for elderly with severe dementia: a pilot 
randomized controlled trial. Am J Alzheimers Dis Other Demen. Epub 
December 1, 2015.
 46. Staal JA, Sacks A, Matheis R, et al. The effects of Snoezelen (multi-
sensory behavior therapy) and psychiatric care on agitation, apathy, and 
activities of daily living in dementia patients on a short term geriatric 
psychiatric inpatient unit. Int J Psychiatry Med. 2007;37:357–370.
 47. Howick J, Chalmers I, Glasziou P, et al. The 2011 Oxford CEBM 
Evidence Levels of Evidence (Introductory Document). Oxford Centre 
for Evidence-Based Medicine. Available from: http://www.cebm.net/
index.aspx?o=5653. Accessed September 28, 2015.
